P1456: EARLY SAFETY AND CLINICAL COURSE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MEASURABLE RESIDUAL DISEASE RECEIVING GTA002, AN OFF-THE-SHELF, EX VIVO-CULTURED ALLOGENEIC NK CELL PREPARATION

• M. Heuser,
• W. Fiedler,
• A. Block,
• D. C. de Leeuw,
• A. van de Loosdrecht,
• A. Astrid Tschan-Plessl,
• J. Passweg,
• A. Kloos,
• A. Schwarzer,
• L. Venturini,
• A. D. Duru,
• K. Pinkernell,
• A. Ganser

Affiliations

M. Heuser

1 Department for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover

W. Fiedler

2 II. Medizinische Klinik und Poliklinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

A. Block

2 II. Medizinische Klinik und Poliklinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

D. C. de Leeuw

3 Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands

A. van de Loosdrecht

3 Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands

A. Astrid Tschan-Plessl

4 Clinical and Diagnostic Hematology, University Hospital Basel, Basel, Switzerland

J. Passweg

4 Clinical and Diagnostic Hematology, University Hospital Basel, Basel, Switzerland

A. Kloos

1 Department for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover

A. Schwarzer

5 Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany

L. Venturini

1 Department for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover

A. D. Duru

6 Glycostem Therapeutics, Oss, Netherlands

K. Pinkernell

6 Glycostem Therapeutics, Oss, Netherlands

A. Ganser

1 Department for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover